Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Buy" by Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has been given an average rating of "Buy" by the six analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $54.20.

A number of equities analysts recently commented on the company. Oppenheimer lifted their price objective on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an "outperform" rating in a research report on Thursday, November 14th. The Goldman Sachs Group lifted their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a report on Friday, November 15th.

Tarsus Pharmaceuticals Stock Down 0.9 %

TARS stock opened at $46.52 on Friday. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The firm has a 50-day moving average of $50.95 and a two-hundred day moving average of $38.27. Tarsus Pharmaceuticals has a 12 month low of $20.08 and a 12 month high of $57.14. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -12.21 and a beta of 1.02.

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of TARS. Canada Pension Plan Investment Board purchased a new position in Tarsus Pharmaceuticals during the second quarter worth about $114,000. FMR LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company's stock worth $166,000 after acquiring an additional 3,537 shares during the last quarter. Dark Forest Capital Management LP purchased a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter worth approximately $202,000. SG Americas Securities LLC boosted its position in shares of Tarsus Pharmaceuticals by 87.5% during the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company's stock worth $238,000 after purchasing an additional 3,379 shares during the period. Finally, Hsbc Holdings PLC acquired a new stake in Tarsus Pharmaceuticals in the 2nd quarter valued at approximately $241,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.